Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEland Oil & Gas Regulatory News (ELA)

  • There is currently no data for ELA

Director/PDMR Shareholding

23 Aug 2005 17:12

Elan Corporation PLC23 August 2005 NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIALRESPONSIBILITY OR CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1). 1. Name of the issuer ELAN CORPORATION PLC 2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a);or (ii) (ii) DR 3.1.4(R)(1)(b) a disclosure made in accordance withsection 324 (as extended by section 328) of the Companies Act 1985 TRANSACTIONNOTIFIED IN ACCORDANCE WITH DR 3.1.4R(1)(b); TRANSACTION NOTIFIED IN ACCORDANCEWITH SECTION 53 OF THE IRISH COMPANIES ACTS 1990; or (iii) (iii) both (i) and (ii) 3. Name of person discharging managerial responsibilities/director GAROARMEN 4. State whether notification relates to a person connected with a persondischarging managerial responsibilities/director named in 3 and identify theconnected person NO 5. Indicate whether the notification is in respect of a holding of theperson referred to in 3 or 4 above or in respect of a non-beneficial interestBENEFICIAL 6. Description of shares (including class), debentures orderivatives or financial instruments relating to shares ORDINARY SHARES OF €0.05EACH REPRESENTED BY AMERICAN DEPOSITARY SHARES 7. Name of registered shareholder(s) and, if more than one, the number ofshares held by each of them PERSON NAMED IN 3 ABOVE 8 State the nature of the transaction PURCHASE - ie EXERCISE OF 200,000 SHARE OPTIONS AND SALE OF 200,000 ADSs 9 Number of shares, debentures or financial instruments relating toshares acquired 200,000 AT $3.84 10. Percentage of issued class acquired (treasury shares of that class shouldnot be taken into account when calculating percentage) 0.047% 11. Number of shares, debentures or financial instruments relating to sharesdisposed 200,000 12. Percentage of issued class disposed (treasury shares of that class shouldnot be taken into account when calculating percentage) 0.047% 13. Price per share or value of transaction $8.2452 14. Date and place of transaction 19 AUGUST 2005 - NEW YORK STOCK EXCHANGE 15. Total holding following notification and total percentage holding followingnotification (any treasury shares should not be taken into account whencalculating percentage) 270,000 - BENEFICIAL 0.063% 16. Date issuer informed of transaction 22 AUGUST 2005 If a person discharging managerial responsibilities has been granted options bythe issuer complete the following boxes 17 Date of grant 18. Period during which or date on which it can be exercised 19. Total amount paid (if any) for grant of the option 20. Description of shares or debentures involved (class and number) 21. Exercise price (if fixed at time of grant) or indication that price is to befixed at the time of exercise 22. Total number of shares or debentures over which options held followingnotification 23. Any additional information NONE 24. Name of contact and telephone number for queries LIAM DANIEL: 017094621 Name and signature of duly authorised officer of issuer responsible for makingnotification LIAM DANIEL - COMPANY SECRETARY Date of notification 22 AUGUST 2005 This announcement has been issued through the Companies Announcement Service of The Irish Stock Exchange This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
17th Jul 20095:57 pmBUSStudies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease
16th Jul 20092:18 pmRNSResults of Annual General Meeting
13th Jul 200911:30 amBUSElan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid
10th Jul 20094:59 pmRNSCancellation of UK Listing
8th Jul 20097:00 amBUSElan Announces Webcast of Second Quarter 2009 Financial Results
3rd Jul 200910:57 amRNSBlock Listing Six Monthly Return
2nd Jul 200912:57 pmRNSHolding in Company
2nd Jul 200912:41 pmPRNJohnson & Johnson, Elan Announce Definitive Agreement
1st Jun 20097:00 amBUSSubset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF? Therapy
29th May 20094:36 pmRNSPrice Monitoring Extension
29th May 20092:00 pmBUSRenee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer
29th May 200911:54 amBUSTotal Voting Rights
30th Apr 200912:16 pmBUSTotal Voting Rights
27th Apr 20093:35 pmRNSAnnual Report
14th Apr 20095:09 pmRNSHolding(s) in Company
27th Feb 20092:44 pmBUSTotal Voting Rights
25th Feb 200912:23 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
9th Feb 20097:00 amBUSMS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
4th Feb 20092:32 pmRNSHolding(s) in Company
3rd Feb 20093:57 pmRNSHolding(s) in Company
30th Jan 20094:33 pmRNSHolding(s) in Company
28th Jan 20094:24 pmRNSHolding(s) in Company
13th Jan 20097:00 amBUSElan Clarifies Duration of Bapineuzumab Phase 3 Trials
12th Jan 20095:21 pmRNSHolding(s) in Company
12th Jan 20097:00 amBUSTysabri Update
2nd Jan 200912:21 pmRNSTotal Voting Rights
18th Dec 20084:24 pmRNSBlock Listing Six Monthly Return
16th Dec 200811:00 amBUSDirector Declaration
16th Dec 20087:00 amBUSElan to Present at the 27th Annual JP Morgan Healthcare Conference
15th Dec 20083:02 pmBUSTysabri Update
12th Dec 20087:00 amBUSElan Announces Resource Realignment
28th Nov 200810:47 amBUSTotal Voting Rights
25th Nov 20087:00 amBUSMary Stutts to Join Elan as Senior Vice President and Head of Corporate Relations
20th Nov 20087:00 amBUSCarlos V. Paya, MD, PhD, to Join Elan as Company President
3rd Nov 20085:12 pmRNSDirector/PDMR Shareholding
31st Oct 20084:11 pmRNSHolding in Company
31st Oct 200812:01 pmRNSTotal Voting Rights
30th Oct 20084:13 pmRNSTysabri Update
3rd Oct 20085:56 pmRNSHolding in Company
30th Sep 20084:11 pmRNSTotal Voting Rights
22nd Sep 200811:26 amRNSHolding In Company
22nd Sep 20087:00 amRNSTysabri Demonstrates Sustained Improvement
11th Sep 20087:39 amRNSDirector /PDMR Shareholding
1st Sep 20085:02 pmRNSHolding(s) in Company
29th Aug 200810:54 amRNSTotal Voting Rights
28th Aug 20087:00 amRNSInterim Results
14th Aug 20084:12 pmRNSHolding in Company
13th Aug 20085:22 pmRNSHolding in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.